Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate

{{Short description|Combination drug}}

{{Drugbox

| type = combo

| drug_name = EDU/OHPH/TCHP

| component1 = Estradiol diundecylate

| class1 = Estrogen

| component2 = Hydroxyprogesterone heptanoate

| class2 = Progestogen

| component3 = Testosterone cyclohexylpropionate

| class3 = Androgen; Anabolic steroid

| tradename = Trioestrine Retard

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration = Intramuscular injection

| CAS_number =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| ChemSpiderID =

| synonyms = EDU/OHPH/TCHP

}}

Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate (EDU/OHPH/TCHP), sold under the brand name Trioestrine Retard, is an injectable combination medication of estradiol diundecylate (EDU), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone cyclohexylpropionate (TCHP), an androgen/anabolic steroid.{{cite journal | vauthors = Herschberg AD | title = [The menopause and the treatment of its disorders by a long-acting multihormone complex: trioestrine lente] | language = fr | journal = Gazette Médicale de France | volume = 67 | pages = 1987–1996 | date = October 1960 | pmid = 13713782 }}{{cite book| vauthors = Krówczyński L |title=Extended Release Dosage Forms|url=https://books.google.com/books?id=tCxtAAAAMAAJ|year=1987|publisher=CRC Press|isbn=978-0-8493-4307-0|page=13|quote=Hydroxyprogesterone heptanoate + testosterone cyclohexylpropionate + oestradiol undecanoate. Trioestrine-RetardR (Theramex). Oily solution for injection.}}{{cite book| vauthors = Kleemann A, Engel J |title= Pharmaceutical substances: syntheses, patents, applications|url=https://books.google.com/books?id=y25qAAAAMAAJ|year=2001|publisher=Thieme|isbn=978-3-13-558404-1|page=1998}} It contained 2.25 mg EDU, 100 mg OHPH, and 67.5 mg TCHP in oil solution, was provided as ampoules, and was administered by intramuscular injection.{{cite journal | last = Bordier | first = Philippe | title = Cure of fifteen osteoporosis cases by a delayed effect of hormonal association | journal = Semaine des Hopitaux | volume = 39 | issue = 2 | pages = 81–4 | year = 1963 | issn = 0037-1777 | quote = The patients (females) received intramuscularly, every 10 days for 2-3 months, estradiol diundecyleate 2.25, testosterone cyclohexylpropionate 67.5, and hydroxyprogesterone heptylate 100 mg. ("trioestrine retard"). Their av. calcuria decreased 30.5% (0-69%) and asthenia, anorexia, and muscular activity improved.}}{{cite book|author=France|title=Journal officiel de la République française|url=https://books.google.com/books?id=YnbpBxDdiD8C|year=1964|quote=Spécialité dénommée Trioestrine retard Theramex, soluté injectable I. M. : [...] Composition : heptylate d'hydroxy-17 alpha-progestérone, 10 g ; cyclohexyl propionate de testostérone, 10 g ; di-undécylate d'œstradiol, 0,5 g ; excipient Q. S. P. 100 ml (en boîtes de 2 ampoules de 1 ml).}} The medication was manufactured by Roussel and Théramex and was marketed by 1953.{{cite book|author=France|title=Journal officiel de la République française|url=https://books.google.com/books?id=VhMkAQAAMAAJ&pg=PA2564|date=March 1953|pages=2564–}} It is no longer available.{{cite web |url=https://www.micromedexsolutions.com/ |title=Home |website=micromedexsolutions.com}}{{cite web | title = Trioestrine | url = https://www.drugs.com/international/trioestrine.html | work = Drugs.com }}{{Dead link|date=March 2024 |bot=InternetArchiveBot |fix-attempted=yes }}